NCT05262530 2026-04-08
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
Phase 1/2 Terminated
BioNTech SE
Prisma Health-Upstate
Zhejiang University
TCRCure Biopharma Ltd.
Nuvation Bio Inc.
Boundless Bio, Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Gustave Roussy, Cancer Campus, Grand Paris
Eli Lilly and Company
Sanofi
MapKure, LLC
L & L Bio Co., Ltd., Ningbo, China
BioNTech SE
Ono Pharmaceutical Co. Ltd
Memorial Sloan Kettering Cancer Center
Noile-Immune Biotech, Inc
Gilead Sciences
BeiGene